Elekta announces preliminary third quarter results
STOCKHOLM, Feb. 14, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) today published preliminary financial results for the third quarter 2021/22. The demand for Elekta's precision radiation medicine solutions continued to be strong in the quarter, driven byEurope and recovery in several emerging markets ...
More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with...
Elekta: Interim report, May-October 2021/22
STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- The increasing need for investments in cancer care and radiotherapy across the globe supported a gradual market recovery during the quarter. Our orders grew with double digits, and despite the continued global supply chain challenges we secured good revenu...
Invitation to the presentation of Elekta's second quarter 2021/22
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the second quarter 2021/22 at10:00 a.m. CET on November 25. The interim report for the second quarter will be published at 7:30 a.m. CET on the same day. The company's development will b...
Award-winning abstracts confirm benefits of Elekta Unity in precision radiation therapy
CHICAGO, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy. The abstracts add to the growing body of data manifesting Elekta Un...
Elekta receives initial investment grade rating from S&P Global Ratings
STOCKHOLM, Oct. 26, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has received an investment grade (IG) rating from S&P Global Ratings (S&P). S&P has assigned a BBB- rating to Elekta and to the Group's senior unsecured notes, with stable outlook. S&P notes that Elekta's rating r...
Elekta acquires Turkish distributor to strengthen market position
STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. (Özyürek A.Ş.). The acquisition will improve Elekta's market access in the region and ...
Elekta Unity MR-Linac featured in 72 abstracts at European radiation oncology congress
MADRID, August 31, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers worldwide, ref...
Year-end report, May-April 2020/21
Accelerated order growth STOCKHOLM, May 28, 2021 /PRNewswire/ -- During Elekta's fourth quarter, we drove strong order growth in all regions – both from market growth and market share gain – and we received our 100th Unity order. Installation volumes were similar to levels in the fourth quarter ...
